NASDAQ : INM
InMed Pharmaceuticals Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Last price 1.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.63M |
| Enterprise Value | 8.40M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.49M |
| Shares Outstanding | 6.64M |
| Shares Change (YoY) | +326.64% |
| Shares Change (QoQ) | +16.06% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 73.66% |
| Float | 3.71M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.95 |
| P/TBV Ratio | 10.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.37 |
| Quick Ratio | 1.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -924.78 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -156.77% |
| Return on Assets (ROA) | -66.46% |
| Return on Invested Capital (ROIC) | -81.10% |
| Return on Capital Employed (ROCE) | -920.47% |
| Weighted Average Cost of Capital (WACC) | 9.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.17M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -13.30% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 72.68 |
| Average Volume (20 Days) | 54,773 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6,634 |
| Short Previous Month | 34,080 |
| Short % of Shares Out | 0.10% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 0.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.90M |
| Pretax Income | -11.37M |
| Net Income | -12.99M |
| EBITDA | -9.69M |
| EBIT | -9.90M |
| Earnings Per Share (EPS) | -$3.12 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.23M |
| Total Debt | n/a |
| Net Cash | 2.23M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 1.08M |
| Book Value Per Share | 0.20 |
| Working Capital | 721,646 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.64M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 205,271 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.64M |
| FCF Per Share | -$1.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -326.64% |
| Shareholder Yield | -326.64% |
| Earnings Yield | -195.03% |
| FCF Yield | -80.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |